Skip to main content
Indian stocks: Visit www.stage2stocks.com →

Penumbra, Inc.

Stage 1 · Basing · week 8

As of Oct 22, 2026, Penumbra is in Stage 1, the basing phase, now in week 8 (since Aug 31, 2026). It closed at $324.96, 9.6% below its 52-week high and below its 200-day average, which is rising.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. More about the company

$324.96
+1.21% today
$12.8B · Large cap
Market Neutral — Building

Pro read

Pro

Our read

Basing, not in an uptrend yet

Setup score

—

Momentum

Steady

Edge

—

Is PEN early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 14w
S4 24w
S2 29w
S2 18w
S3 18w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S3 5w → S4 14w → S1 12w → S4 24w → S1 10w → S2 29w → S3 7w → S4 6w → S1 8w → S4 3w → S1 1w → S2 18w → S3 18w → S4 2w → S1 8w current
Total tracked: 165 weeks across 15 stage runs.

PEN among Medical Devices24th of 141 by relative strength

All 141 →
Stocks in Medical Devices ranked by relative strength, with stage and one-month change
#StockStageRS1M
1TXGStage 2 · wk 4899−7.8%
2RCELStage 2 · wk 1398+40.8%
3BFLYStage 2 · wk 2698−26.0%
4HAEStage 2 · wk 1796+8.7%
5GKOSStage 2 · wk 2596+15.1%
6AXGNStage 3 · wk 295−15.3%
7NEOGStage 2 · wk 1495−11.7%
8BVSStage 2 · wk 1595+10.5%
…24PENStage 1 · wk 877+1.7%
vs 52W High
-9.6%
$225.54 lo$359.40 hi
9.6% below 52W high, pullback range
Stock is basing below old highs. A volume-backed breakout to new highs would be the Stage 2 signal to watch.
Stage Maturity
Week 8
1w13w26w
Week 8, base building
How long this stock has been basing. Longer bases can produce stronger breakouts, but the breakout itself is the signal.
vs 200 DMA
-0.7%
200 DMA: $327.25 · rising
Stock is testing its 200 DMA as part of the base. Reclaiming and holding above it is a key Stage 2 prerequisite.
Rel Volume
1.42x
vs 50-day avg
Volume in Stage 1 basing is typically quiet. A surge in volume on an upside breakout is the signal to watch.
Trend Health
→
Short-term trend flat
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+1.7%
3M
+2.0%
6M
-2.4%
YTD
+5.0%
1Y
+30.5%
Scan Membership
Breakout Watch
Latest: 2024-11-18
12 appearances in last 60 days. First seen: 2018-10-16.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S1
Wk 8 · Vol 1.42x
2026-10-21S1
Wk 8 · Vol 1.08x
2026-10-20S1
Wk 8 · Vol 1.14x
2026-10-19S1
Wk 7 · Vol 0.84x
2026-10-16S1
Wk 7 · Vol 0.86x
2026-10-15S1
Wk 7 · Vol 1.07x
2026-10-14S1
Wk 7 · Vol 0.84x
2026-10-13S1
Wk 7 · Vol 0.66x
2026-10-12S1
Wk 6 · Vol 0.85x
2026-10-09S1
Wk 6 · Vol 1.72x
2026-10-08S1
Wk 6 · Vol 1.18x
2026-10-07S1
Wk 6 · Vol 1.13x
Moving averages & range
50 DMA
$320.92
200 DMA
$327.25
52W High
$359.40
52W Low
$225.54
5D Low
$320.86
Resistance levels (recent highs)
20d High
$324.96
60d High
$327.17
120d High
$328.69
250d High
$359.40
Next resistance
+0.7%
to 60d High
P/E (TTM)
79.8
Forward 53.1
Earnings Growth (YoY)
-23.5%
Revenue +14.9%
ROE
+11.4%
Profit margin +10.7%
Dividend Yield
0.00%
P/B 8.4

Penumbra: quick answers

What stage is Penumbra in?

As of Oct 22, 2026, Penumbra (PEN) is in Stage 1, the basing phase. It entered Stage 1 on Aug 31, 2026 and is in week 8. What the four stages mean

Is Penumbra in an uptrend?

Not yet. Penumbra is in Stage 1, a base that can come before an uptrend. It trades 0.7% below its 200-day average, which is rising.

How far is Penumbra from its 52-week high?

Penumbra closed at $324.96 on Oct 22, 2026, 9.6% below its 52-week high of $359.40. Its 52-week low is $225.54.

How has Penumbra performed over the past year?

As of Oct 22, 2026, Penumbra is up 30.5% over the past year and up 5.0% so far in 2026.

Which sector and industry is Penumbra in?

Penumbra is in the Medical Devices industry, part of the Health Care sector.

About this companyHealth Care· Medical Devices

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.